.css-1gu7o1h p{color:#FFFFFF;font-weight:600;font-size:1rem;}.css-1gu7o1h .typo{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;}.css-1hgicv7{box-sizing:border-box;-webkit-flex-direction:row;-ms-flex-direction:row;flex-direction:row;}.css-1hgicv7 p{color:#FFFFFF;font-weight:600;font-size:1rem;}.css-1hgicv7 .typo{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;}

JavaScript is currently disabled in your browser. For the best experience, please enable JavaScript to enjoy full website functionality. Thank you!

Steps to Enable JavaScript

hero-and-search-large

IQVIA is a global leader in the field of clinical research.

Our team supports hundreds of trials around the world, giving patients the opportunity to explore new treatment options

1/6

Cardiovascular Diseases

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)

To assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug improves disease-related biomarkers and slows the rate of progression of cognitive or clinical impairment.

2/6

Cardiovascular Diseases

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)

To assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug improves disease-related biomarkers and slows the rate of progression of cognitive or clinical impairment.

See if you qualify

3/6

Asthma

Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma

This is a randomised, placebo-controlled, double-blind study to assess the efficacy and safety of Atuliflapon administered at multiple dose levels over a 12-week treatment period to adult participants with moderate to severe uncontrolled asthma.

See if you qualify

4/6

Cardiovascular Diseases

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)

To assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug improves disease-related biomarkers and slows the rate of progression of cognitive or clinical impairment.

5/6

Asthma

Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma

This is a randomised, placebo-controlled, double-blind study to assess the efficacy and safety of Atuliflapon administered at multiple dose levels over a 12-week treatment period to adult participants with moderate to severe uncontrolled asthma.

See if you qualify

6/6

Cardiovascular Diseases

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)

To assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug improves disease-related biomarkers and slows the rate of progression of cognitive or clinical impairment.

Understand Clinical Research1

Every new medication, treatment approach, preventive therapy, and medical device must undergo testing and evaluation before being approved for utilization as a standard of patient care. This is commonly known as the field of Clinical Research. Without the important work of clinical research professionals, the breakthrough findings of scientists would never translate into available treatments and quality of life benefits for patients.

about-clinical-research

About clinical research

Role-of-participant

The role of participants

How-to-participate

How to participate

Latest News

Alzheimer's Disease

How much do you know about Alzheimer's dementia?

Discover some common early symptoms and signs of Alzheimer's dementia

2023-01-30T18:30:00Z

Asthma

How much do you know about Alzheimer's dementia?

Discover some common early symptoms and signs of Alzheimer's dementia

2023-03-14T18:30:00Z

Asthma

How much do you know about Alzheimer's dementia?_Test_EE

Discover some common early symptoms and signs of Alzheimer's dementia

2023-03-14T18:30:00Z